5
Orphan Designations
0 approved, 5 designated
0
FDA Approvals
0
Active Trials
7
Rare Diseases
across 19 areas
0
News (30d)
Quiet
Guangzhou Sinogen Pharmaceutical Co., Ltd. is a company with 5 orphan drug designations across 7 rare diseases. 1 active policy bill affects their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| hepatocellular carcinoma | a genetically modified salmonella comprising of methioninase | Des.TrialAppr. |
| malignant carotid body paraganglioma | a genetically modified Salmonella comprising of methioninase | Des.TrialAppr. |
| malignant pancreatic neoplasm | SalMet-Vec (a genetically modified Salmonella comprising of methioninase) | Des.TrialAppr. |
| nasopharyngeal carcinoma | genetically modified Salmonella comprising of methioninase | Des.TrialAppr. |
| post-treatment Lyme disease syndrome | a genetically modified Salmonella comprising of methioninase | Des.TrialAppr. |
| small cell lung carcinoma | a genetically modified Salmonella comprising of methioninase | Des.TrialAppr. |
| treatment-refractory schizophrenia | a genetically modified Salmonella comprising of methioninase | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
111
overlap in 2+ diseases
0/7
candidate diseases
0
avg importance: 0
1
affecting portfolio
0% of portfolio targets high unmet need diseases
111
overlap in 2+ diseases
0/7
candidate diseases
0
avg importance: 0
1
affecting portfolio